Travere Therapeutics Reports Second Quarter 2022 Financial Results

SAN DIEGO , Aug. 04, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application (NDA) for accelerated approval of sparsentan in IgA nephropathy (IgAN) accepted by the U.S.